An Effective New Option for Refractory Hodgkin Lymphoma

Outcomes with haploidentical stem-cell transplantation plus cyclophosphamide were similar to those with matched related or unrelated donor transplantation.

Hodgkin lymphoma (HL) patients who have treatment-refractory disease or who fail autologous stem-cell transplantation (SCT) may be cured by allogeneic SCT.

Now, European investigators have performed a retrospective study of 709 patients with relapsed or refractory HL to compare the effectiveness of haploidentical allogeneic SCT (HAPLO) plus post-SCT cyclophosphamide versus traditional matched related- or unrelated donor allogeneic SCT. Following re-induction therapy, 98 patients received HAPLO, 338 received HLA-matched sibling donor SCT (SIB), and 273 received matched unrelated donor (MUD) SCT.

Two-year overall survival was similar among patients receiving HAPLO, SIB, or MUD (67%, 71%, and 62%). The composite endpoint of relapse-free survival…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

An Effective New Option for Refractory Hodgkin Lymphoma

Topics

Reviewing Author